

## DAFTAR PUSTAKA

- Adib. M. 2009. Cara Mudah Memahami dan Menghindari Hipertensi Jantung dan Stroke. Dianloka Pustaka Populer, Yogyakarta.
- Albu Adriana, Ioana Para & Mihai Porojan, 2020, Uric Acid and Arterial Stiffness, Department of Internal Medicine, ,University of Medicine and Pharmacy, Cluj-Napoca, Romania
- Andrikou Ioannis, Costas Tsioufis & Dimitris Konstantinidis, 2018, Renal resistive index in hypertensive patients, Cardiology Department, Hippocraton Hospital, Athens, Greece
- Aiumtrakul Noppawit, Puvanant Wiputhanuphongs, Ouppatham Supasyndh et al. 2020, Hyperuricemia and Impaired Renal Function: A Prospective Cohort Study, Department of Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand
- Baxter, G.M. Ultrasound of the Urogenital System . Thieme.Stuttgart 2005. NewYork
- Berni A, Boddi M & Bissoni E, 2010,Serum Uric Acid Levels and Renal Damage in Hyperuricemic Hypertensive Patients Treated With Renin–Angiotensin System Blockers, Department of Medical and Surgical Critical Care, University of Florence, Italy
- Bigel Naike, Pierre Patrick, Patrice Callard et al ,2012, Renal arterial resistive index is associated with severe histological changes and poor renal outcome during chronic kidney disease, Department of Nephrology, Paris

Boddi M,. Renal Ultrasound (and Doppler Sonography) in hypertension : An Update. 2017, Springer International Publishing. Switzerland

Calabia Jordi, Pere Torquet, Isabel Garcia et al, 2014, The Relationship Between Renal Resistive Index, Arterial Stiffness, and Atherosclerotic Burden: The Link Between Macrocirculation and Microcirculation, Department of Nephrology, University Hospital Dr. Josep Trueta, University of Girona, Girona, Spain.

Chang Chun-Chin, Cheng-Hsueh Wu et all, 2018, Association between serum uric acid and cardiovascular risk in nonhypertensive and nondiabetic individuals: The Taiwan I-Lan Longitudinal Aging Study, Taipei Medical University, Taipei, Taiwan.

Cheng Y and Yan Li, 2017, Hyperuricemia Does It Matter for the Progression From Prehypertension to Hypertension?, Shanghai Institute of Hypertension, Shanghai Jiao Tong University School of Medicine, China

Chini L.S.N, L.I.S. Assis and J.R. Lugon, 2017, Relationship between uric acid levels and risk of chronic kidney disease in a retrospective cohort of Brazilian workers Departament Medicina, University Federal Fluminense, Niteroi, Brasil

Derchi Lorenzo E, Giovanna Leoncini, Denise Parodi, et al, 2005, Mild Renal Dysfunction and Renal Vascular Resistance in Primary Hypertension, Departments of Radiology-DICMI and Internal Medicine, University of Genoa, Genoa, Italy.

- Douglas J, Langlois V, & Noone D, 2020, Hyperuricemia and Hypertension: Links and Risks, Division of Nephrology, University of Toronto, Canada
- Fan S, Ping Zhang & Amanda Ying Wang, 2019, Hyperuricemia and its related histopathological features on renal biopsy, BMC Nephrology, Renal Department and Nephrology Institute, Sichuan Provincial People's Hospital, China
- Fiorini, F., & Barozzi, L. (2007). *The role of ultrasonography in the study of medical nephropathy. Journal of Ultrasound, 10(4), 161–167.* doi:10.1016/j.jus.2007.09.001
- Filiopoulos V, Dimitrios Hadjiyannakos & Dimosthenis Vlassopoulos, 2012, New Insights into Uric Acid Effects on the Progression and Prognosis of Chronic Kidney Disease, Department of Nephrology, “Amalia Fleming” General Hospital, Athens, Greece
- Fruchart JC, Nierman MC, Stroes ES, 2004, New risk factors for atherosclerosis and patient risk assessment, AHA Journals
- Gibson Larry and Fambrough Valerie, 2018, Anatomy and Physiology I&II, Gross anatomy of the kidney, Galileo, University of North Georgia , Creative Commons Attribution 4.0 International License
- Giulio G, Giuseppe M& Manuela M, 2016, Association Between Uric Acid and Renal Hemodynamics: Pathophysiological Implications for Renal Damage in Hypertensive Patients, Unit of Nephrology and Hypertension, University of Palermo, Italy

- Hussein AM, Botros SM, Saleh S.A, 2015, Relation between hyper-uricemia and renal resistivity index in non diabetic non hypertensive patients, Radiology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
- Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, Takishita S, 2001, Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects, Hypertens Res.
- Iwao Ohno, 2011, Relationship Between Hyperuricemia and Chronic Kidney Disease, Department of Internal Medicine, Division of Kidney and Hypertension, Jikei University School of Medicine, Tokyo, Japan
- Johnson Richard J. , Duk-Hee K & Daniel F, 2003 Is There a Pathogenetic Role for Uric Acid in hypertension and Cardiovascular and Renal Disease?, Division of Nephrology, Institut of Cardiology, Mexico City, Mexico.
- Kadir Akmarawita , 2016, Hubungan Patofisiologi Hipertensi dan Hipertensi Renal, Jurnal Imiah Kedokteran Volume 5 Nomer 1, Bagian Ilmu Faal Fakultas Kedokteran Universitas Wijaya Kusuma, Surabaya
- Kamis Fatih, Serkan Bakirdogen, Ayse Burcu Cam, 2021, The relationship between renal resistive index and simple hematologic indices in patients with chronic kidney disease, Canakkale Onsekiz Mart University, School of Medicine, Department of Internal Medicine, Canakkale, Turkey

- Kang Duke-Hee, Takahiko Nakagawa et al, 2002, A Role for Uric Acid in the Progression of Renal Disease, Division of Nephrology, Baylor College of Medicine, Houston, Texas, University of Washington
- Kaplan NM, 2015. Primary Hypertension: Patogenesis. In: Kaplan's Clinical Hypertension. Edisi 11, Philadelphia: Lippincot Williams and Wilkins.
- Kelly Christoper R and Landman Jaime, 2012 The Netter Collection of Medical Illustrations : Urinary System, Edisi 2, Volume 5, Elsevier Saunder, Department in Philadelphia, USA
- Kemenkes R.I. 2018 Riset Kesehatan Dasar; RISKESDAS. Jakarta : Balitbang Kemenkes R.I.
- Krumme Bernd & Markus Hohenbeck, 2007, Doppler sonography in renal artery stenosis—does the Resistive Index predict the success of intervention?, *Nephrology Dialysis Transplantation*, Volume 22
- Lerma Edgar, Mathew S, & Joel T, 2018, Nephrology Secret, Edisi 4, Philadelphia, Elsevier
- Lioso, 2014, Hubungan antara umur, jenis kelamin dan Index Massa Tubuh dengan kadar asam urat pada masyarakat yang datang berkubjubf di Puskesmas Paniki Bawah Kota Manado
- Liu B et al, 2011. The Prevalence of hyperurisemia in china : a metaanalysis. BMC Public Health
- Mc Adam et al, 2013, Risk factors during mild-Adulthood in African American and white men and women enrolled in the ARIC cohort study, BMC Musculoskelet Disord

Noer Sjaifoellah, 1996, Buku Ajar Ilmu Penyakit Dalam, Balai Penerbit FKUI, Jakarta

Oliver Jones, 2019, The kidney – position – structure – vasculature, Teachmeanatomy

Pontremoli R, Francesca Viazzi, Carlo Martinoli et al, 1999, Serum Uric Acid as a Risk Factor for Cardiovascular and Renal Disease : An Old Controversy Revived, Departmenr of internal Medicine, Institute of Radiology, and Departmen of Neuroscience and Neurorehabilitation, University of Genoa, Genoa, Italy

Radermacher Jorg, Sebastian Ellis, Hermann Haller, 2002, Renal Resistance Index and Progression of Renal Disease, Department of Nephrology, Hannover Medical School, Hannover, Germany

Ramirez J, Gabriela Sanchez-Lozada & Magdalena Madero, 2017, Uric Acid, Vascular Stiffness, and Chronic, Kidney Disease: Is There a Link?, National Institute of Medical Sciences and Nutrition Salvador Zubirán (INCMNSZ)), and National Heart Institute, Mexico City , Mexico

Romil Muhammad M, Nur Arfian, Untung Tranggono et al, 2017, Uric acid causes kidney injury through inducing fibroblast expansion, Endothelin-1 expression, and inflammation, Department of Anatomy, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia

Saxena, T., Ali, A. O., & Saxena, M. 2018. Pathophysiology of essential hypertension: an update. Expert Review of Cardiovascular Therapy. doi:10.1080/14779072.2018.1540301.

Sharaf E.U, Mona M Salemb & Dina O Abdulazim, 2016, Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A Review, Nephrology, Endocrinology and Rheumatology unit Department, School of Medicine, Cairo University, Egypt

Silva, N.R., Goncalves, C.E.T., Goncalves, D.L.N. *et al.*, 2021, Association of uric acid and uric acid to creatinine ratio with chronic kidney disease in hypertensive patients, Department of Nutrition and Health, Federal University of Vicosa, Minas Gerais, Vicosa, Brazil

Simon Steddin,et all, 2014, Oxford Handbook of Nephrology and Hypertension, Oxford University, United Kingdom, Edisi 2

Sonoda Hiroo, Hiroyuki Takase, Yasuaki Dohi, Genjiro Kimura, 2011, Uric Acid Levels Predict Future Development of Chronic Kidney Disease, Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences, Nagoya , Japan

Tuma, J., Trinkler, F. Zat'ura, F. Novakova, B. 2009. *Genitourinary ultrasound. EFSUMB European course book.*  
<http://www.efsumb.org/ecb/ecb-ch09-urogenital.pdf>

Tublin M.E, Ronal O Bude, Joe F Platt, 2003, The Resistive Index in Renal Doppler Department of Radiology, University of Pittsburgh School of Medicine, AJR

- Viazzi, F., Leoncini G, Ratto E, Pontremoli R, 2007, Mild Hyperuricemia and Subclinical Renal Damage in Untreated Primary Hypertension, University San Martino, Italy
- Viazzi, F., Leoncini G, Ratto E, Pontremoli R,, 2014. Hyperuricemia and Renal Risk, University San Martino, Italy
- Viazzi, F., Leoncini, G., Derchi, L. E., Pontremoli, R. et al 2014. Ultrasound Doppler renal resistive index: a useful tool for the management of the hypertensive patient, Journal of Hypertension, University San Martino, Italy
- Viazzi F, Grassib G & Pontremoli R, 2016, Can we predict outcome by noninvasive assessment of renal haemodynamics in hypertension? The role of renal resistive index, Journal of Hypertension, Universitas san Martino, Italy
- Viazzi, F., Denise Parodi, Giovanna Leoncini, Elena Ratto & Roberto Pontremoli, 2005, Serum Uric Acid and Target Organ Damage in Primary Hypertension, Department of Internal Medicine, University of Genoa and the Department of Cardioneurology, San Martino, Italy
- Weiner DE, Tighiourt H, Elsayed EF, Griffith JL, Salem JN, 2008, Uric Acid and incident Kidney Disease in the community, Jurnal American Society of Nephrology
- Yulanda G, Lisiswanti Rika. Penatalaksanaan Hipertensi Primer. 2017;6(1):28-33. Bandar Lampung



## LAMPIRAN 1

## Data Penelitian

No	Nama	RM	JK	Umur	Asam Urat	eGFR	stadium	RRI		Riw dislipidemia	HT	Non HT	Lamanya hiperurisemia
								Kanan	Kiri				
1	O	938741	L	48	8.5	88.6	Stad 2	0.62	0.61	√		√	< 6 bulan
2	A	937774	L	19	7.5	129.0	Stad 1	0.51	0.53	-		√	< 6 bulan
3	S	661300	P	47	6.8	49.3	Stad 3A	0.58	0.62	√	√		4 tahun
4	N	892724	P	55	7.3	7.9	Stad 5	0.71	0.72	√	√		< 6 bulan
5	R	939208	P	41	6.9	120.2	Stad 1	0.59	0.50	-		√	1 tahun
6	N	904892	P	52	6.3	104.8	Stad 1	0.52	0.56	-		√	2 tahun
7	R	927930	P	39	6.0	91.5	Stad 1	0.53	0.59	-	√		< 6 bulan
8	A	946599	L	36	9.5	118	Stad 1	0.59	0.58	-		√	< 6 bulan
9	I	942045	P	32	9.1	116	Stad 1	0.56	0.52	-		√	< 6 bulan
10	M	689826	P	49	6.4	48.6	Stad 3A	0.62	0.55	-		√	2 tahun
11	H	952849	L	23	7.1	125.9	Stad 1	0.48	0.47	-	√		< 6 bulan
12	I	815716	L	41	8.6	82.9	Stad 2	0.48	0.50	-	√		4 tahun
13	E	875083	P	49	7.5	58.6	Stad 3A	0.66	0.66	-		√	2 tahun
14	Y	921085	P	35	7.7	104.1	Stad 1	0.52	0.53	√	√		1 tahun
15	H	865957	P	57	7.1	81.8	Stad 2	0.61	0.67	-	√		3 tahun

16	I	946844	L	73	8.1	73.8	Stad 2	0.58	0.56	-		√	< 6 bulan
17	S	65491	L	55	8.4	101	Stad 1	0.67	0.60	-		√	2 tahun
18	N	915487	P	67	7.8	60.4	Stad 2	0.65	0.63	√	√		< 6 bulan
19	H	10277	P	56	7.6	82.4	Stad 2	0.63	0.62	√	√		8 tahun
20	A	801370	P	56	8.3	82.4	Stad 2	0.57	0.54	√		√	< 6 bulan
21	H	353961	P	53	6.1	105.2	Stad 1	0.61	0.61	√	√		1 tahun
22	M	950509	L	34	9.1	78.4	Stad 2	0.50	0.52	-		√	< 6 bulan
23	Z	952239	L	58	7.3	70.5	Stad 2	0.52	0.53	-		√	< 6 bulan
24	K	922161	P	43	6.5	111,6	Stad 1	0.56	0.55	-	√		< 6 bulan
25	A	350026	L	70	9.7	43.7	Stad 3B	0.71	0.61	-		√	< 6 bulan
26	A	569680	P	34	6.4	78.4	Stad 2	0.53	0.53	-		√	6 tahun
27	D	941695	P	32	6.2	137.8	Stad 1	0.50	0.49	-		√	< 6 bulan
28	S	948560	L	32	7.3	79.5	Stad 2	0.54	0.54	√		√	< 6 bulan
29	N	952166	L	33	7.8	114.5	Stad 1	0.52	0.51	-		√	< 6 bulan
30	H	926882	P	54	7.3	56.9	Stad 3A	0.63	0.61	-		√	< 6 bulan
31	R	954293	P	52	7.4	12.5	Stad 5	0.70	0.71	-	√		< 6 bulan
32	M	842196	P	53	6.9	73	Stad 2	0.68	0.66	-	√		5 tahun
33	S	941489	P	48	17.2	32.7	Stad 3B	0.63	0.70	√	√		< 6 bulan
34	B	306661	L	57	7.6	62.2	Stad 2	0.60	0.61	√	√		3 tahun

35	A	843022	P	61	7.2	93.5	Stad 1	0.55	0.55	√		√	3 tahun
36	Y	956552	L	50	8.1	97.9	Stad 1	0.59	0.68	-		√	< 6 bulan
37	R	843022	P	62	8.1	68.5	Stad 2	0.55	0.55	√		√	3 tahun
38	A	957314	L	26	7.7	114.4	Stad 1	0.58	0.60	-		√	< 6 bulan
39	N	950906	P	48	8.3	87.2	Stad 2	0.66	0.62	-		√	< 6 bulan
40	H	944354	P	53	6.7	98.9	Stad 1	0.51	0.49	-		√	< 6 bulan
41	S	689269	P	65	8.7	67.1	Stad 2	0.62	0.63	-		√	< 6 bulan
42	A	934172	L	43	7.5	91.8	Stad 1	0.57	0.58	-		√	< 6 bulan
43	I	907203	L	46	8.6	50.9	Stad 3A	0.63	0.62	-		√	2 tahun
44	M	900184	L	53	7.1	80.6	Stad 2	0.63	0.63	√		√	2 tahun
45	A	961052	P	39	7,2	109,1	Stad 1	0.61	0.63	-		√	< 6 bulan
46	M	640898	P	29	12. 4	8.2	Stad 5	0.64	0.67	-	√		8 tahun
47	S	311171	L	42	8.8	82. 4	Stad 2	0.52	0.51	√		√	6 tahun
48	H	564853	L	60	9.8	41.1	Stad 3B	0.74	0.73	√	√		7 tahun
49	H	716294	P	34	6.8	120	Stad 1	0.59	0.57	-		√	5 tahun
50	I	852783	L	32	7.5	95.7	Stad 1	0.48	0.46	-		√	3 tahun
51	H	579753	L	57	6.2	71	Stad 2	0.59	0.53	√	√		3 tahun
52	N	554350	P	59	6.3	70	Stad 2	0.62	0.62	-		√	5 tahun
53	S	757744	P	53	9.0	104.1	Stad 1	0.62	0.60	-		√	5 tahun

54	S	875095	P	54	7.9	98.2	Stad 1	0.60	0.62	-	√		2 tahun
55	H	947176	P	50	7.1	86	Stad 2	0.58	0.57	√		√	< 6 bulan

## LAMPIRAN 2

**Tests of Normality**

	Kolmogorov-Smirnov <sup>a</sup>			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
RRI Kanan	.094	55	.200*	.974	55	.266
RRI Kiri	.087	55	.200*	.984	55	.659
eGFR	.072	55	.200*	.958	55	.055

\*. This is a lower bound of the true significance.

**Descriptive Statistics**

	Mean	Std. Deviation	N
eGFR	80.6964	31.69670	55
RRI_ka	.5909	.06237	55

**Correlations**

		eGFR	RRI_ka
eGFR	Pearson Correlation	1	-.486**
	Sig. (2-tailed)		.000
	N	55	55
RRI_ka	Pearson Correlation	-.486**	1
	Sig. (2-tailed)	.000	
	N	55	55

\*\* . Correlation is significant at the 0.01 level (2-tailed).

### Correlations

			eGFR	RRI_ka
Spearman's rho	eGFR	Correlation Coefficient	1.000	-.477**
		Sig. (2-tailed)	.	.000
		N	55	55
	RRI_ka	Correlation Coefficient	-.477**	1.000
		Sig. (2-tailed)	.000	.
		N	55	55

\*\* . Correlation is significant at the 0.01 level (2-tailed).

### Descriptive Statistics

	Mean	Std. Deviation	N
eGFR	80.6964	31.69670	55
RRI_ki	.5869	.06460	55

### Correlations

		eGFR	RRI_ki
eGFR	Pearson Correlation	1	-.512**
	Sig. (2-tailed)		.000
	N	55	55
RRI_ki	Pearson Correlation	-.512**	1
	Sig. (2-tailed)	.000	
	N	55	55

\*\* . Correlation is significant at the 0.01 level (2-tailed).

### Correlations

			eGFR	RRI_ki
Spearman's rho	eGFR	Correlation Coefficient	1.000	-.477**
		Sig. (2-tailed)	.	.000
		N	55	55
	RRI_ki	Correlation Coefficient	-.477**	1.000
		Sig. (2-tailed)	.000	.
		N	55	55

\*\* . Correlation is significant at the 0.01 level (2-tailed).

### T-Test

Group Statistics				
Hipertensi	N	Mean	Std. Deviation	Std. Error Mean
RRI_ka ya	21	.6138	.06622	.01445
tidak	34	.5768	.05629	.00965

Independent Samples Test										
		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
									Lower	Upper
RRI_ka	Equal variances assumed	.026	.873	2.216	53	.031	.03704	.01672	.00352	.07057
	Equal variances not assumed			2.132	37.328	.040	.03704	.01738	.00185	.07224

## T-Test

Group Statistics

Hipertensi	N	Mean	Std. Deviation	Std. Error Mean
RRI_ki ya	21	.6210	.06848	.01494
tidak	34	.5659	.05286	.00907

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
									Lower	Upper
RRI_ki	Equal variances assumed	.346	.559	3.349	53	.001	.05507	.01644	.02209	.08805
	Equal variances not assumed			3.151	34.594	.003	.05507	.01748	.01957	.09057

## T-Test

Group Statistics

Dislipidemia	N	Mean	Std. Deviation	Std. Error Mean
RRI_ka ya	18	.6072	.05644	.01330
tidak	37	.5830	.06429	.01057

Independent Samples Test

		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
									Lower	Upper
RRI_ka	Equal variances assumed	1.016	.318	1.364	53	.178	.02425	.01778	-.01142	.05992
	Equal variances not assumed			1.427	38.067	.162	.02425	.01699	-.01014	.05864



## T-Test

**Group Statistics**

Dislipidemia	N	Mean	Std. Deviation	Std. Error Mean
RRI_ki ya	18	.6039	.06418	.01513
tidak	37	.5786	.06404	.01053

**Independent Samples Test**

		Levene's Test for Equality of Variances		t-test for Equality of Means						
		F	Sig.	t	df	Sig. (2-tailed)	Mean Difference	Std. Error Difference	95% Confidence Interval of the Difference	
									Lower	Upper
RRI_ki	Equal variances assumed	.175	.677	1.371	53	.176	.02524	.01842	-.01170	.06218
	Equal variances not assumed			1.369	33.719	.180	.02524	.01843	-.01223	.06271

## LAMPIRAN 3



KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN  
 FAKULTAS KEDOKTERAN UNIVERSITAS HASANUDDIN  
 KOMITE ETIK PENELITIAN KESEHATAN

Sekretariat : Lantai 2 Gedung Laboratorium Terpadu  
 JL. PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10, Makassar Telp.0411-5780103, Fax (0411) 581431.  
 Contact person dr. Aguzalim Bukhari MMed, PhD, Sp.GK (HP. 081241850858), email: aguzalimbukhari@yahoo.com.

## Lampiran

**PERSETUJUAN SETELAH PENJELASAN**  
 (Informed consent)

Saya yang bertanda tangan di bawah ini

Nama :  
 Umur/Kelamin :  
 Alamat :

Bukti diri/KTP:

Dengan ini menyatakan dengan sesungguhnya serta memberikan persetujuan dan bersedia menjalani/mengikuti penelitian ini, setelah mendapat penjelasan dari peneliti (dokter) dan mengerti sepenuhnya tentang prosedur penelitian yang akan dilakukan. Demikian pernyataan ini saya buat dengan penuh kesadaran dan tanpa paksaan dari pihak manapun.

Saksi-saksi Tanggal :  
 Tanda tangan : Yang membuat pernyataan,

1. (.....) (.....)
2. (.....)

Tempat meminta penjelasan :

Pejabat Peneliti

Pejabat medis (Dr yang merawat)

Nama : dr. Atika Puspa Dewi  
 Alamat : BTP Perumahan Tamalaurea Mas blok M1 No 17  
 Telepon(HP) : 085396998408

Penanggungjawab medis : dr. Nurlaily Idris, Sp.Rad (K)  
 Alamat : Jalan Sunu Kompleks UNHAS blok H 14 Makassar  
 Telepon(HP) : 081342110987

## LAMPIRAN 4

**REKOMENDASI PERSETUJUAN ETIK**

Nomor : 639/UN4.6.4.5.31/ PP36/ 2021

Tanggal: 5 Oktober 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21090568		No Sponsor Protokol	
Peneliti Utama	<b>dr. Atika Puspa Dewi</b>		Sponsor	
Judul Peneliti	Korelasi eGFR dengan Renal Resistive Index (RRI) pada pasien hiperurisemia			
No Versi Protokol	2	Tanggal Versi	16 September 2021	
No Versi PSP	2	Tanggal Versi	16 September 2021	
Tempat Penelitian	RS Dr. Wahidin Sudirohusodo Makassar			
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal		Masa Berlaku 5 Oktober 2021 sampai 5 Oktober 2022	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama <b>Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)</b>		Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama <b>dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)</b>		Tanda tangan	

## Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

## LAMPIRAN 5

**CURRICULUM VITAE****A. Data Pribadi**

Nama : dr. Atika Puspa Dewi  
Tempat/Tanggal Lahir : Bengkulu, 22 April 1984  
Alamat : BTP Blok M1 No.17. Perumahan Tamalanrea Mas,  
Kota Makassar  
Agama : Islam

**B. Riwayat Pendidikan**

- SD : SD N 61 Bengkulu, lulus tahun 1996
- SMP : SLTP N 14 Bengkulu, lulus tahun 1999
- SMA : SMU N 2 Bengkulu, lulus tahun 2002
- Strata-1 (Pendidikan Dokter) : Fakultas Kedokteran Universitas Malahayti, Bandar Lampung, angkatan 2003, lulus tahun 2010
- Program Pendidikan Dokter Spesialis-1 : Departemen Radiologi Fakultas Kedokteran Universitas Hasanuddin, Makassar, Periode Januari 2018

**C. Riwayat Pekerjaan**

- Dokter Umum RSUD Mukomuko, Mukomuko, Bengkulu, tahun 2011-2016
- Dokter Umum Puskesmas Sukarami, Bengkulu Tengah, Bengkulu, Tahun 2016-2017

**D. Riwayat Keluarga**

- Ayah : Drs. H. Syaukani Dahari
- Ibu : Hj. Lely Sulastri
  
- Saudara Kandung : dr. Anita Indah Sari, Terry Olivianti, dr. Novian Adi Saputra
- Istri : Kiki Stiawan, S.IP, MH
- Anak : Darrell Alvaro Stiawan

**E. Karyallmiah/Artikel yang telah dipublikasikan**

-

**F. Makalah pada Seminar/Konferensillmiah Nasional dan Internasional**

*Hipoplasia Pulmo Sinistra dengan VACTERL Syndrom*, Jakarta, 27-28 Juli 2019